Circulating concentrations of bile acids and prevalent chronic kidney disease among newly diagnosed type 2 diabetes: a cross-sectional study

Tingting Geng,Qi Lu,Limiao Jiang,Kunquan Guo,Kun Yang,Yun-Fei Liao,Meian He,Gang Liu,Huiru Tang,An Pan
DOI: https://doi.org/10.1186/s12937-024-00928-2
2024-03-04
Nutrition Journal
Abstract:The relationship between circulating bile acids (BAs) and kidney function among patients with type 2 diabetes is unclear. We aimed to investigate the associations of circulating concentrations of BAs, particularly individual BA subtypes, with chronic kidney disease (CKD) in patients of newly diagnosed type 2 diabetes.
nutrition & dietetics
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the relationship between the concentration of bile acids (BAs) in circulation, especially each BAs subtype, and chronic kidney disease (CKD) in newly diagnosed type 2 diabetes patients. Specifically, the study aims to investigate the association between the concentrations of major and minor unconjugated BAs and their taurine - or glycine - conjugated forms in circulation and CKD, in the hope of providing new perspectives and potential biomarkers for the protection of renal function in type 2 diabetes patients. ### Research Background Type 2 diabetes (T2D) is a global public health crisis with high morbidity and mortality. Diabetic nephropathy is one of its main microvascular complications, affecting nearly 50% of diabetic patients. Therefore, it is crucial to identify interventions that can prevent or delay the decline of renal function in diabetic patients. Bile acids (BAs), as important signaling molecules, play a key role in maintaining lipid and glucose homeostasis by activating specific receptors such as G - protein - coupled bile acid receptor 1 (GPBAR1) and nuclear farnesoid X receptor (FXR). Previous studies have shown that circulating BAs are positively correlated with obesity, insulin resistance and diabetes, and the activation of BAs receptors can protect the kidneys from damage. ### Research Methods This study is a cross - sectional study, including 1,234 newly diagnosed type 2 diabetes patients from the Dongfeng Tongji Cohort. The concentrations of major and minor unconjugated BAs and their taurine - or glycine - conjugated forms in circulation were measured using ultra - high - performance liquid chromatography - tandem mass spectrometry (UPLC - MS/MS). CKD was defined as an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m². Logistic regression models were used to calculate the odds ratio (OR) and 95% confidence interval (CI). ### Main Results - **Main Findings**: After adjusting for multiple tests, higher levels of total major BAs (OR per standard deviation increment: 0.78; 95% CI: 0.65 - 0.92), cholic acid (OR: 0.78; 95% CI: 0.66 - 0.92), chenodeoxycholic acid (OR: 0.81; 95% CI: 0.69 - 0.96), glycocholic acid (OR: 0.81; 95% CI: 0.68 - 0.96) and glycochenodeoxycholic acid (OR: 0.82; 95% CI: 0.69 - 0.97) were associated with a lower probability of CKD in newly diagnosed type 2 diabetes patients. - **Secondary Findings**: No significant relationship was observed between minor BAs and the incidence of CKD. ### Conclusions The study results indicate that higher concentrations of circulating unconjugated major BAs and their glycine - conjugated forms, rather than taurine - conjugated forms or minor BAs, are associated with a lower probability of CKD in type 2 diabetes patients. These findings may be helpful for the early detection of CKD in type 2 diabetes patients and provide a basis for adjusting treatment strategies. ### Potential Mechanisms Although the exact mechanism is not fully understood, the activation of bile acid receptors (such as FXR and GPBAR1) may directly protect renal function by reducing inflammation, renal oxidative stress and lipid accumulation. In addition, the expression of these receptors can induce an effect similar to caloric restriction, thereby reversing age - related kidney damage. ### Clinical Applications - **Biomarkers**: Specific BAs can be used as biomarkers for the early detection of CKD in type 2 diabetes patients. - **Treatment Strategies**: Explore treatment methods to regulate BAs levels to prevent or delay the progression of CKD. - **Monitoring**: Emphasize the importance of regular monitoring of renal function and BAs to take preventive measures. ### Research Limitations - **Cross - sectional Design**: It is impossible to determine the temporal relationship, and the relationship between BAs and CKD may be bidirectional. - **CKD Definition**: CKD is defined only based on eGFR, lacking quantitative data on urinary albumin, which may lead to misclassification. - **Lack of Chronic Data**: There is no chronic data on eGFR, and acute kidney disease cases cannot be completely excluded. - **Lack of End - stage Renal Disease Information**: It is impossible to explore the relationship between BAs and more severe stages of CKD. Future studies need to include prospective data and a larger sample size to better understand the relationship between BAs profiles and the decline of renal function.